10-Year-Old Arthritis Institute Goes Beyond Aches And Pains Of Joints

And Pains Of Joints (The Scientist, Vol:10, #6, p. 13 & 18, March 18, 1996) SEEKING ADVICE: New NIAMS director Stephen Katz is consulting all sectors of the biomedical community to help set institutional priorities. "Chronic, common, costly, and crippling." That's how Stephen I. Katz, director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) since August, describes the diseases that the institute explores. NIAMS is celebrating its 10th anniversary this year

Written byKaren Young Kreeger
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

And Pains Of Joints (The Scientist, Vol:10, #6, p. 13 & 18, March 18, 1996)

Stephen Katz
SEEKING ADVICE: New NIAMS director Stephen Katz is consulting all sectors of the biomedical community to help set institutional priorities.
"Chronic, common, costly, and crippling." That's how Stephen I. Katz, director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) since August, describes the diseases that the institute explores. NIAMS is celebrating its 10th anniversary this year.

According to NIAMS statistics, one in seven Americans has some form of arthritis; one in three Americans has a serious skin disease; and four of five Americans will have lower back pain at some point in their lives. "We cover over 100 forms of arthritis, all of the musculoskeletal system-from osteoporosis to low back pain to repetitive motion disorders to muscle diseases-and all of the skin diseases. In addition, we cover basic research on the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies